BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: File TM Jr. Appropriate use of antimicrobials for drug-resistant pneumonia: focus on the significance of beta-lactam-resistant Streptococcus pneumoniae. Clin Infect Dis 2002;34 Suppl 1:S17-26. [PMID: 11810607 DOI: 10.1086/324526] [Cited by in Crossref: 64] [Cited by in F6Publishing: 47] [Article Influence: 3.2] [Reference Citation Analysis]
Number Citing Articles
1 Tan TQ. Antibiotic resistant infections due to Streptococcus pneumoniae: impact on therapeutic options and clinical outcome. Curr Opin Infect Dis 2003;16:271-7. [PMID: 12821820 DOI: 10.1097/00001432-200306000-00015] [Cited by in Crossref: 34] [Cited by in F6Publishing: 27] [Article Influence: 1.8] [Reference Citation Analysis]
2 Pírez García M, Giachetto Larraz G, Romero Rostagno C, Zabala Chain C, Algorta Rusiñol G, Montano Lotito A, Ferrari Castilla A. Neumonía neumocócica invasiva en niños de 0 a 24 meses: ¿influye la resistencia bacteriana en la evolución? Anales de Pediatría 2008;69:205-9. [DOI: 10.1157/13125812] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
3 Giachetto G, Pirez MC, Nanni L, Mart??nez A, Montano A, Algorta G, Kaplan SL, Ferrari AM. Ampicillin and Penicillin Concentration in Serum and Pleural Fluid of Hospitalized Children With Community-Acquired Pneumonia: . The Pediatric Infectious Disease Journal 2004;23:625-9. [DOI: 10.1097/01.inf.0000128783.11218.c9] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 0.7] [Reference Citation Analysis]
4 Moellering RC Jr. The continuing challenge of lower respiratory tract infections. Clin Infect Dis 2002;34 Suppl 1:S1-3. [PMID: 11810605 DOI: 10.1086/324524] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
5 Patria MF, Tagliabue C, Longhi B, Esposito S. Influenza vaccination in children at high risk of respiratory disease. Ther Adv Vaccines 2013;1:21-31. [PMID: 24757513 DOI: 10.1177/2051013613480770] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 1.9] [Reference Citation Analysis]
6 Mera RM, Miller LA, Amrine-Madsen H, Sahm DF. Impact of new Clinical Laboratory Standards Institute Streptococcus pneumoniae penicillin susceptibility testing breakpoints on reported resistance changes over time. Microb Drug Resist 2011;17:47-52. [PMID: 21117969 DOI: 10.1089/mdr.2010.0129] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
7 Johnson JR. Doxycycline for Treatment of Community‐Acquired Pneumonia. CLIN INFECT DIS 2002;35:632-632. [DOI: 10.1086/341983] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 0.7] [Reference Citation Analysis]
8 Elawamy M, Mohammad H, Hussien A, Abutaleb NS, Hagras M, Serya RA, Taher AT, Abouzid KA, Seleem MN, Mayhoub AS. Alkoxyphenylthiazoles with broad-spectrum activity against multidrug-resistant gram-positive bacterial pathogens. European Journal of Medicinal Chemistry 2018;152:318-28. [DOI: 10.1016/j.ejmech.2018.04.049] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
9 Potts BE, Hart ML, Snyder LL, Boyle D, Mosier DA, Chapes SK. Differentiation of C2D macrophage cells after adoptive transfer. Clin Vaccine Immunol 2008;15:243-52. [PMID: 18094115 DOI: 10.1128/CVI.00328-07] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
10 Parrino TA. Controlled Trials to Improve Antibiotic Utilization: A Systematic Review of Experience, 1984–2004. Pharmacotherapy 2005;25:289-98. [DOI: 10.1592/phco.25.2.289.56951] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 1.2] [Reference Citation Analysis]
11 Finch R. Bacterial resistance--the clinical challenge. Clin Microbiol Infect 2002;8 Suppl 3:21-32; discussion 33-5. [PMID: 12519346 DOI: 10.1046/j.1469-0691.8.s.3.3.x] [Cited by in Crossref: 36] [Cited by in F6Publishing: 28] [Article Influence: 1.9] [Reference Citation Analysis]
12 An MM, Zou Z, Shen H, Gao PH, Cao YB, Jiang YY. Moxifloxacin monotherapy versus β-lactam-based standard therapy for community-acquired pneumonia: a meta-analysis of randomised controlled trials. International Journal of Antimicrobial Agents 2010;36:58-65. [DOI: 10.1016/j.ijantimicag.2010.03.010] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
13 File TM. The development of pharmacokinetically enhanced amoxicillin/clavulanate for the management of respiratory tract infections in adults. International Journal of Antimicrobial Agents 2007;30:131-4. [DOI: 10.1016/j.ijantimicag.2007.07.038] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
14 Lambregts M, Rump B, Ropers F, Sijbom M, Petrignani M, Visser L, de Vries M, de Boer M. Antimicrobial guidelines in clinical practice: incorporating the ethical perspective. JAC Antimicrob Resist 2021;3:dlab074. [PMID: 34235435 DOI: 10.1093/jacamr/dlab074] [Reference Citation Analysis]
15 File TM. Judicious use of antibiotics to treat respiratory tract infections: . Current Opinion in Infectious Diseases 2002;15:149-50. [DOI: 10.1097/00001432-200204000-00008] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
16 File TM Jr, Niederman MS. Antimicrobial therapy of community-acquired pneumonia. Infect Dis Clin North Am 2004;18:993-1016, xi. [PMID: 15555836 DOI: 10.1016/j.idc.2004.07.011] [Cited by in Crossref: 32] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
17 Feldman C. Clinical relevance of antimicrobial resistance in the management of pneumococcal community-acquired pneumonia. Journal of Laboratory and Clinical Medicine 2004;143:269-83. [DOI: 10.1016/j.lab.2004.02.002] [Cited by in Crossref: 45] [Cited by in F6Publishing: 30] [Article Influence: 2.5] [Reference Citation Analysis]
18 Zhanel GG, Johanson C, Hisanaga T, Mendoza C, Laing N, Noreddin A, Wierzbowski A, Hoban DJ. Pharmacodynamic activity of telithromycin against macrolide-susceptible and macrolide-resistant Streptococcus pneumoniae simulating clinically achievable free serum and epithelial lining fluid concentrations. Journal of Antimicrobial Chemotherapy 2004;54:1072-7. [DOI: 10.1093/jac/dkh475] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 0.9] [Reference Citation Analysis]
19 Schlemmer B, Jury de la conférence de consensus. Comment améliorer la qualité de l’antibiothérapie dans les établissements de soins ? Médecine et Maladies Infectieuses 2003;33:593-610. [DOI: 10.1016/s0399-077x(03)00198-7] [Cited by in Crossref: 4] [Article Influence: 0.2] [Reference Citation Analysis]
20 Hanachi M, Kiran A, Cornick J, Harigua-Souiai E, Everett D, Benkahla A, Souiai O. Genomic Characteristics of Invasive Streptococcus pneumoniae Serotype 1 in New Caledonia Prior to the Introduction of PCV13. Bioinform Biol Insights 2020;14:1177932220962106. [PMID: 33088176 DOI: 10.1177/1177932220962106] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
21 English BK, Buckingham SC. Impact of antimicrobial resistance on therapy of bacterial pneumonia in children. Adv Exp Med Biol 2006;582:125-35. [PMID: 16802624 DOI: 10.1007/0-387-33026-7_11] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
22 Cunha BA. Empiric Therapy of Community-Acquired Pneumonia. Chest 2004;125:1913-9. [DOI: 10.1378/chest.125.5.1913] [Cited by in Crossref: 22] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
23 Álvarez-rocha L, Alós J, Blanquer J, Álvarez-lerma F, Garau J, Guerrero A, Torres A, Cobo J, Jordá R, Menéndez R, Olaechea P, Rodríguez de castro F. Guías para el manejo de la neumonía comunitaria del adulto que precisa ingreso en el hospital. Medicina Intensiva 2005;29:21-62. [DOI: 10.1016/s0210-5691(05)74199-1] [Cited by in Crossref: 5] [Article Influence: 0.3] [Reference Citation Analysis]
24 Martinez FJ. Monotherapy versus Dual Therapy for Community-Acquired Pneumonia in Hospitalized Patients. Clinical Infectious Diseases 2004;38:S328-40. [DOI: 10.1086/382689] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 1.2] [Reference Citation Analysis]
25 Jackson LA, Neuzil KM. Pneumococcal polysaccharide vaccines. Vaccines. Elsevier; 2008. pp. 569-604. [DOI: 10.1016/b978-1-4160-3611-1.50028-3] [Cited by in Crossref: 10] [Article Influence: 0.7] [Reference Citation Analysis]
26 Strålin K, Kaltoft MS, Konradsen HB, Olcén P, Holmberg H. Comparison of two urinary antigen tests for establishment of pneumococcal etiology of adult community-acquired pneumonia. J Clin Microbiol 2004;42:3620-5. [PMID: 15297507 DOI: 10.1128/JCM.42.8.3620-3625.2004] [Cited by in Crossref: 53] [Cited by in F6Publishing: 17] [Article Influence: 2.9] [Reference Citation Analysis]
27 Daoud Z, Cocozaki A, Hakime N. Antimicrobial susceptibility patterns of Haemophilus influenzae and Streptococcus pneumoniae isolates in a Beirut general university hospital between 2000 and 2004. Clinical Microbiology and Infection 2006;12:86-90. [DOI: 10.1111/j.1469-0691.2005.01303.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
28 File T. Clinical implications and treatment of multiresistant Streptococcus pneumoniae pneumonia. Clinical Microbiology and Infection 2006;12:31-41. [DOI: 10.1111/j.1469-0691.2006.01395.x] [Cited by in Crossref: 44] [Cited by in F6Publishing: 42] [Article Influence: 2.8] [Reference Citation Analysis]
29 Rapp RP, Ribes JA, Overman SB, Darkow TE, Evans ME. A Decade of Antimicrobial Susceptibilities at the University of Kentucky Hospital. Ann Pharmacother 2002;36:596-604. [DOI: 10.1345/aph.1a249] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
30 File TM Jr. Streptococcus pneumoniae and community-acquired pneumonia: a cause for concern. Am J Med 2004;117 Suppl 3A:39S-50S. [PMID: 15360096 DOI: 10.1016/j.amjmed.2004.07.007] [Cited by in Crossref: 5] [Cited by in F6Publishing: 31] [Article Influence: 0.3] [Reference Citation Analysis]
31 Katz E, Larsen L, Fogarty CM, Hamed K, Song J, Choudhri S. Safety and efficacy of sequential i.v. to p.o. moxifloxacin versus conventional combination therapies for the treatment of community-acquired pneumonia in patients requiring initial i.v. therapy. The Journal of Emergency Medicine 2004;27:395-405. [DOI: 10.1016/j.jemermed.2004.02.023] [Cited by in Crossref: 32] [Cited by in F6Publishing: 24] [Article Influence: 1.8] [Reference Citation Analysis]
32 Ewig S, Torres A. Severe community-acquired pneumonia. Curr Opin Crit Care 2002;8:453-60. [PMID: 12357115 DOI: 10.1097/00075198-200210000-00014] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
33 File TM. Telithromycin new product overview. Journal of Allergy and Clinical Immunology 2005;115:S361-73. [DOI: 10.1016/j.jaci.2004.11.029] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
34 File TM Jr, Lode H, Kurz H, Kozak R, Xie H, Berkowitz E; 600 Study Group. Double-blind, randomized study of the efficacy and safety of oral pharmacokinetically enhanced amoxicillin-clavulanate (2,000/125 milligrams) versus those of amoxicillin-clavulanate (875/125 milligrams), both given twice daily for 7 days, in treatment of bacterial community-acquired pneumonia in adults. Antimicrob Agents Chemother 2004;48:3323-31. [PMID: 15328092 DOI: 10.1128/AAC.48.9.3323-3331.2004] [Cited by in Crossref: 29] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
35 Rutala WA, Weber DJ. Registration of disinfectants based on relative microbicidal activity. Infect Control Hosp Epidemiol 2004;25:333-41. [PMID: 15108732 DOI: 10.1086/502401] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.1] [Reference Citation Analysis]
36 Rosenblüt A, Santolaya ME, Gonzalez P, Borel C, Cofré J. Penicillin resistance is not extrapolable to amoxicillin resistance in Streptococcus pneumoniae isolated from middle ear fluid in children with acute otitis media. Ann Otol Rhinol Laryngol 2006;115:186-90. [PMID: 16572607 DOI: 10.1177/000348940611500305] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 0.8] [Reference Citation Analysis]
37 Tan JS, File TM Jr. Management of community-acquired pneumonia: a focus on conversion from hospital to the ambulatory setting. Am J Respir Med 2003;2:385-94. [PMID: 14719991 DOI: 10.1007/BF03256666] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
38 File TM. Current Challenges in the Treatment of Community-Acquired Pneumonia. Clinical Infectious Diseases 2004;38:S1-4. [DOI: 10.1086/378404] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
39 File TM Jr. Clinical efficacy of newer agents in short-duration therapy for community-acquired pneumonia. Clin Infect Dis 2004;39 Suppl 3:S159-64. [PMID: 15546111 DOI: 10.1086/421354] [Cited by in Crossref: 47] [Cited by in F6Publishing: 34] [Article Influence: 2.8] [Reference Citation Analysis]
40 File TM, Garau J, Jacobs MR, Wynne B, Twynholm M, Berkowitz E. Efficacy of a new pharmacokinetically enhanced formulation of amoxicillin/clavulanate (2000/125 mg) in adults with community-acquired pneumonia caused by Streptococcus pneumoniae, including penicillin-resistant strains. Int J Antimicrob Agents 2005;25:110-9. [PMID: 15664480 DOI: 10.1016/j.ijantimicag.2004.10.007] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 0.7] [Reference Citation Analysis]
41 Fogarty C, Torres A, Choudhri S, Haverstock D, Herrington J, Ambler J. Efficacy of moxifloxacin for treatment of penicillin-, macrolide- and multidrug-resistant Streptococcus pneumoniae in community-acquired pneumonia: MOXIFLOXACIN EFFICACY AGAINST MDRSP. International Journal of Clinical Practice 2005;59:1253-9. [DOI: 10.1111/j.1368-5031.2005.00699.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
42 Siquier B, Sánchez-Alvarez J, García-Mendez E, Sabriá M, Santos J, Pallarés R, Twynholm M, Dal-Ré R; 620 Clinical Study Group. Efficacy and safety of twice-daily pharmacokinetically enhanced amoxicillin/clavulanate (2000/125 mg) in the treatment of adults with community-acquired pneumonia in a country with a high prevalence of penicillin-resistant Streptococcus pneumoniae. J Antimicrob Chemother 2006;57:536-45. [PMID: 16446376 DOI: 10.1093/jac/dki480] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
43 Ruhe JJ, Myers L, Mushatt D, Hasbun R. High‐Level Penicillin‐Nonsusceptible Streptococcus pneumoniae Bacteremia: Identification of a Low‐Risk Subgroup. CLIN INFECT DIS 2004;38:508-14. [DOI: 10.1086/381197] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
44 Alvarez-Lerma F, Grau S, Gracia-Arnillas MP. Gram-positive cocci infections in intensive care: guide to antibacterial selection. Drugs 2006;66:751-68. [PMID: 16706550 DOI: 10.2165/00003495-200666060-00003] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
45 Esposito S, Marchisio P, Cavagna R, Gironi S, Bosis S, Lambertini L, Droghetti R, Principi N. Effectiveness of influenza vaccination of children with recurrent respiratory tract infections in reducing respiratory-related morbidity within the households. Vaccine 2003;21:3162-8. [PMID: 12804844 DOI: 10.1016/s0264-410x(03)00253-6] [Cited by in Crossref: 75] [Cited by in F6Publishing: 33] [Article Influence: 4.2] [Reference Citation Analysis]
46 Garau J. Role of beta-lactam agents in the treatment of community-acquired pneumonia. Eur J Clin Microbiol Infect Dis 2005;24:83-99. [DOI: 10.1007/s10096-005-1287-9] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.0] [Reference Citation Analysis]
47 File TM. Community-acquired pneumonia. Lancet 2003;362:1991-2001. [PMID: 14683661 DOI: 10.1016/S0140-6736(03)15021-0] [Cited by in Crossref: 329] [Cited by in F6Publishing: 142] [Article Influence: 18.3] [Reference Citation Analysis]